

Douglas T Dieterich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1334705/publications.pdf>

Version: 2024-02-01

82
papers

4,517
citations

279798

23
h-index

98798

67
g-index

84
all docs

84
docs citations

84
times ranked

4127
citing authors

#	ARTICLE	IF	CITATIONS
1	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. <i>Gut</i> , 2022, 71, 2069-2080.	12.1	24
2	Polycystic Kidney/Liver Disease. <i>Clinics in Liver Disease</i> , 2022, 26, 229-243.	2.1	5
3	Liver Transplantation for Hepatitis D Virus in the United States: A UNOS Study on Outcomes in the MELD Era. <i>Transplantation Direct</i> , 2022, 8, e1253.	1.6	8
4	Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2022, 77, 642-652.	3.7	17
5	First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alafenamide. <i>Hepatology Communications</i> , 2022, 6, 1881-1894.	4.3	7
6	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. <i>Oncogene</i> , 2021, 40, 140-151.	5.9	77
7	Emerging prevalence of fatty liver disease in HIV. <i>Future Virology</i> , 2021, 16, 59-73.	1.8	1
8	Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways. <i>Advances in Therapy</i> , 2021, 38, 1397-1403.	2.9	4
9	Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 329-338.	3.2	14
10	Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. <i>American Journal of Transplantation</i> , 2020, 20, 220-230.	4.7	33
11	Improving Advance Care Planning in Outpatients With Decompensated Cirrhosis: A Pilot Study. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 864-870.	1.2	7
12	Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1311-1322.	3.7	11
13	Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. <i>Gastroenterology</i> , 2020, 159, 1985-1987.e4.	1.3	83
14	<p></p>Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 515-526.	1.9	9
15	Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir+dasabuvir+sofosbuvir in the TOPAZ-1 and TOPAZ-2 trials. <i>Journal of Viral Hepatitis</i> , 2020, 27, 497-504.	2.0	10
16	Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation. <i>JAMA Network Open</i> , 2020, 3, e2027551.	5.9	13
17	Liver Disease in Human Immunodeficiency Virus Infection. <i>Clinics in Liver Disease</i> , 2019, 23, 309-329.	2.1	4
18	Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and Ñ2M in the ION-4 Study Cohort. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy273.	0.9	9

#	ARTICLE	IF	CITATIONS
19	Reducing mother-to-child transmission of HCV: Is it attainable with a multidisciplinary approach?. <i>Journal of Hepatology</i> , 2019, 71, 229-230.	3.7	2
20	Necrolytic acral erythema in a human immunodeficiency virus/hepatitis C virus coinfecting patient: A case report. <i>World Journal of Hepatology</i> , 2019, 11, 226-233.	2.0	3
21	Multimethod assessment of baseline depression and relationship to hepatitis C treatment discontinuation. <i>International Journal of Psychiatry in Medicine</i> , 2018, 53, 256-272.	1.8	0
22	Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation. <i>Clinics in Liver Disease</i> , 2018, 22, 213-227.	2.1	16
23	Direct-acting antiviral treatment of acute hepatitis C virus infections. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 599-610.	4.4	3
24	Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfecting with HIV and HCV genotype-1: a Phase III, open-label study. <i>Hepatology International</i> , 2017, 11, 188-198.	4.2	2
25	Sofosbuvir in the treatment of early HCV infection in HIV-infected men. <i>HIV Clinical Trials</i> , 2017, 18, 60-66.	2.0	22
26	Management of Patients With Hepatitis C Virus, Monoclonal Gammopathy of Undetermined Significance, and Multiple Myeloma. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2017, 5, 232470961769685.	0.6	0
27	American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. <i>Gastroenterology</i> , 2017, 152, 1544-1577.	1.3	208
28	Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin. <i>Journal of NeuroVirology</i> , 2017, 23, 260-272.	2.1	7
29	Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. <i>World Journal of Hepatology</i> , 2017, 9, 551.	2.0	2
30	Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. <i>World Journal of Virology</i> , 2017, 6, 59-72.	2.9	7
31	Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. <i>Annals of Hepatology</i> , 2016, 15, 333-349.	1.5	1
32	Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus. <i>PLoS ONE</i> , 2016, 11, e0159413.	2.5	65
33	The use of generics to treat chronic hepatitis C: not quite ready for the big stage. <i>Liver International</i> , 2016, 36, 933-935.	3.9	6
34	About This Continuing Medical Education Activity. <i>Clinical Infectious Diseases</i> , 2016, 63, S1-S2.	5.8	0
35	Prospective comparison of magnetic resonance imaging to transient elastography and serum markers for liver fibrosis detection. <i>Liver International</i> , 2016, 36, 659-666.	3.9	54
36	Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 511-521.	4.4	16

#	ARTICLE	IF	CITATIONS
37	Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV. <i>Clinical Infectious Diseases</i> , 2016, 62, 1497-1504.	5.8	23
38	Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. <i>Hepatology</i> , 2016, 64, 1893-1899.	7.3	61
39	Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, S3-S11.	5.8	49
40	C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients. <i>Annals of Translational Medicine</i> , 2016, 4, S12-S12.	1.7	6
41	Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2016, 22, 2844.	3.3	5
42	HCV vertical transmission in pregnancy: New horizons in the era of DAAs. <i>Hepatology</i> , 2015, 62, 1656-1658.	7.3	46
43	Development of sofosbuvir for the treatment of hepatitis C virus infection. <i>Annals of the New York Academy of Sciences</i> , 2015, 1358, 56-67.	3.8	31
44	Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. <i>New England Journal of Medicine</i> , 2015, 373, 714-725.	27.0	382
45	Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. <i>New England Journal of Medicine</i> , 2015, 373, 705-713.	27.0	432
46	Faldaprevir and pegylated interferon α -2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. <i>Aids</i> , 2015, 29, 571-581.	2.2	17
47	Hepatitis C: Diagnosis, Management and Treatment. , 2014, , 58-77.		0
48	Hepatitis B and D. , 2014, , 41-57.		1
49	HIV/HCV and HIV/HBV Co-infections. , 2014, , 78-95.		0
50	SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α -2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3429-3436.	3.2	13
51	Treating HCV in HIV 2013: on the cusp of change. <i>Liver International</i> , 2014, 34, 53-59.	3.9	7
52	Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 353.	7.4	236
53	HIV-Hepatitis C Virus Co-infection in the era of Direct-Acting Antivirals. <i>Current HIV/AIDS Reports</i> , 2014, 11, 241-249.	3.1	12
54	Telaprevir Activity in Treatment-Naive Patients Infected With Hepatitis C Virus Genotype 4. <i>Journal of Infectious Diseases</i> , 2014, 210, 1855-1856.	4.0	1

#	ARTICLE	IF	CITATIONS
55	Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study. <i>Clinical Infectious Diseases</i> , 2014, 59, 1579-1587.	5.8	63
56	Hepatitis C Direct-Acting Antiviral Agents in HIV/HCV Co-infected Patients. <i>Current Treatment Options in Infectious Diseases</i> , 2014, 6, 132-143.	1.9	1
57	Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting Antivirals. <i>Drugs</i> , 2014, 74, 951-961.	10.9	9
58	Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Mono-infection Treatment. <i>Gastroenterology and Hepatology</i> , 2014, 10, 706-715.	0.1	0
59	Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV. <i>Annals of Internal Medicine</i> , 2013, 159, 86-96.	3.9	179
60	Management of the Cirrhotic Patient. , 2013, , 517-525.		0
61	The end of the beginning for hepatitis C treatment. <i>Hepatology</i> , 2012, 55, 664-665.	7.3	4
62	Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon- α -2a and ribavirin in HIV/HCV co-infected patients. <i>Journal of Hepatology</i> , 2011, 54, 41-47.	3.7	21
63	Management of Hepatitis B Virus Coinfection: HIV, Hepatitis C Virus, Hepatitis D Virus. <i>Current Hepatitis Reports</i> , 2011, 10, 262-268.	0.3	1
64	Dual therapy for chronic hepatitis B virus. <i>Current Hepatitis Reports</i> , 2008, 7, 33-39.	0.3	0
65	Effect of Baseline CD4 Cell Count on the Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Patients With HIV/Hepatitis C Virus Coinfection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 36-49.	2.1	62
66	Viral hepatitis in patients with HIV infection. <i>Current Hepatitis Reports</i> , 2007, 6, 103-113.	0.3	0
67	Special considerations and treatment of patients with HBV-HIV coinfection. <i>Antiviral Therapy</i> , 2007, 12 Suppl 3, H43-51.	1.0	1
68	Special Considerations and Treatment of Patients with HBV-HIV Coinfection. <i>Antiviral Therapy</i> , 2007, 12, 43-51.	1.0	6
69	Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. <i>Journal of Clinical Virology</i> , 2006, 36, 283-291.	3.1	21
70	Treatment Issues in Patients With HIV/HCV Co-Infection. <i>Gastroenterology and Hepatology</i> , 2006, 2, 789-790.	0.1	0
71	Management of chronic Hepatitis C virus in patients with HIV. <i>Current Treatment Options in Gastroenterology</i> , 2005, 8, 433-441.	0.8	4
72	Epoetin Alfa Once Weekly Improves Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated With Interferon/Ribavirin: A Randomized Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 504-506.	2.1	35

#	ARTICLE	IF	CITATIONS
73	Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients. <i>New England Journal of Medicine</i> , 2004, 351, 438-450.	27.0	1,220
74	Daily Versus Thrice-Weekly Interferon Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Persons: A Multicenter Randomized Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 35, 464-472.	2.1	21
75	Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. <i>Aids</i> , 2004, 18, 21-25.	2.2	132
76	Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. <i>American Journal of Gastroenterology</i> , 2003, 98, 2491-2499.	0.4	208
77	Toxicity of Non-Nucleoside Analogue Reverse Transcriptase Inhibitors. <i>Seminars in Liver Disease</i> , 2003, 23, 173-182.	3.6	85
78	HIV and hepatitis B virus: options for managing coinfection. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2003, 11, 16-9.	2.9	1
79	Long-term complications of nucleoside reverse transcriptase inhibitor therapy. <i>Aids Reader</i> , 2003, 13, 176-84, 187.	0.3	22
80	Hepatotoxicity of antiretroviral therapy. <i>AIDS Reviews</i> , 2003, 5, 36-43.	1.0	64
81	Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV/HCV International Panel. <i>Aids</i> , 2002, 16, 813-828.	2.2	280
82	Management of Hepatitis B in HIV-Infected and other Immunosuppressed Patients. , 0, , 174-180.		0